Background: Although the history of treating alopecia with hair transplantation spans over 60 years, the literature providing evidence for the use of this method in patients with alopecia caused by lichen planopilaris (LPP) is extremely limited and primarily consists of isolated case reports. It has been suggested that these data may be subject to publication bias. Here, we describe a case series of five consecutive patients with LPP who underwent hair transplantation using the follicular unit extraction technique. Methods: Patient satisfaction was assessed twice (6 months and >12 months after transplantation), on a 5-point Likert scale, where 1 indicated no satisfaction at all and 5 indicated high satisfaction. Results: In the near follow-up, two patients reported strong dissatisfaction (40%), two patients were rather satisfied (40%), and one patient was very satisfied. In two cases, multiple surgeries were required to achieve a positive outcome. According to the physicians, all cases exhibited a positive therapeutic effect, which was documented with photographs. No complications were observed. In the extended follow-up, all patients declared satisfaction. Conclusions: Hair regrowth in patients with LPP is possible, despite the common belief that hair loss in LPP is irreversible.
Objectives: Our study aimed to establish the basic reliability parameters of direct immunofluorescence test results in patients with oral lichen planus. Methods: We conducted an evaluation of individual antibody classes in the DIF and ELISA (BP180 antigen), comparing these results with the classical histopathological (HP) examination in a group of patients treated within the standard healthcare in our clinic. Results: Among 66 participants with oral changes indicative of LP, only 50% received histopathological confirmation of the LP diagnosis. Among those with a DIF profile entirely typical for LP (C3+, F+), 57.1% had a positive HP result. Fibrinogen deposits were identified in 42.4% and 36.4% of individuals with positive HP results for F1 and F2, respectively; 78.8% of patients with negative HP and 57.6% with positive HP exhibited no fibrinogen deposits. Simultaneous positivity for F1 and F2 occurred in all cases where F1 was positive. HP confirmed positive DIF for C3 in 50% of cases. Fibrinogen deposits demonstrated the highest diagnostic accuracy (61%). Sensitivity and specificity for fibrinogen deposits were 36% and 42% for F1 and 79% and 82% for F2. The positive predictive values were 67% for F1 and 67% for F2, while the negative predictive values were 58% for F1 and 56% for F2. Overall diagnostic accuracy was reported at 61% for F1 and 59% for F2. Conclusions: Our data indicate the complementarity of HP and immunological test results and the necessity of using both methods together in cases of doubt.
Background/Objectives: Pemphigus vulgaris (PV) and foliaceus (PF) are autoimmune blistering diseases mediated by IgG antibodies directed against desmogleins 1 and 3 and are still considered life-threatening disorders. In recent years, rituximab has been shown to be very effective, especially in PV and mainly in short follow-ups. The role of rituximab in achieving long-lasting complete clinical remission (cCR) in pemphigus still needs to be determined. Therefore, the aim of our study was to assess the efficacy, measured by achieving long-lasting cCR, and safety of rituximab in both PV and PF over an 8-year follow-up in light of several factors (body mass index—BMI, severity of disease—PDAI, age, gender, disease duration, COVID-19 period). Methods: In total, 28 patients with pemphigus were treated with rituximab and followed-up at one center. The entire analysis was performed using statistical methods. Results: Long-lasting cCR was achieved in 5 out of 6 patients (83%) with PF and 10 of 22 (45.5%) patients with PV. Univariate and multivariate analysis disclosed that studied factors did not statistically correlated with achieving long-lasting cCR. Among studied patients, few developed side effects, mainly urinary tract infection; one patient had sepsis, and one patient died. Conclusions: This study has demonstrated that rituximab is highly effective in PF and quite effective in PV over an 8-year follow-up in relation to independently studied factors. Moreover, the COVID-19 pandemic was not a negative factor influencing cCR achievement since 82% of patients treated with rituximab during that time still achieved cCR.
Objective: Numerous reports describe the typical localization of lesions in the oral cavity in various conditions, manifesting as oral lesions. We aimed to evaluate the correlation between these lesions and the results of histopathological examinations (HP). Methods: We examined 66 consecutive patients with oral lesions consistent with the clinical presentation of oral lichen planus (OLP). Standard HP evaluation was performed using light microscopy and, subsequently, the association between the precise location of the lesion and the histopathological diagnosis was assessed. Results: Erosions on the mandibular gingiva (p = 0.0086), white patches on the right buccal mucosa (p = 0.03197), white patches on the ventral surface of the tongue (p = 0.0397), white patches on the maxillary gingiva (p = 0.0228), white patches on the mandibular gingiva (p = 0.0062), white patches on the upper lip (p = 0.0226), and bilateral white patches on the buccal mucosa (p = 0.0104) were significantly more prevalent in patients with positive histopathological findings. White patches on the buccal mucosa emerged as the strongest predictor of histopathological diagnosis of OLP, with a sensitivity of 91.3% and a negative predictive value of 85.7%. Conclusions: The location of oral lesions may indicate OLP with high sensitivity and a negative predictive value, which may facilitate further diagnostic management; however, it is not sufficient to establish a definitive diagnosis.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, predominantly affecting elderly patients with multiple comorbidities. This multicentre retrospective cohort study aimed to characterize the clinical profile, treatment patterns, and drug-associated cases of BP in a real-world setting. The study included 156 patients newly diagnosed with BP between 2020 and 2024 in four dermatology departments in Poland. Diagnosis was based on clinical features, and immunological assessment, including direct immunofluorescence (DIF), ELISA, and BIOCHIP-based indirect immunofluorescence. The mean age at diagnosis was 75.5 ± 10.9 years, and 78.85% of patients had at least one comorbidity, most commonly arterial hypertension, type 2 diabetes mellitus, and dyslipidemia. Severe pruritus was reported in 74.14% of evaluated patients. Blisters and erosions were the predominant clinical manifestations. Topical glucocorticosteroids were the most frequently used treatment, followed by systemic glucocorticosteroids and methotrexate. New drug exposure within 6 months before disease onset was identified in 14.74% of patients and was associated with a shorter time to diagnosis. Drug-associated cases showed lower BP180 ELISA positivity, although this did not remain significant after correction for multiple testing. These findings highlight the clinical complexity of BP and the importance of medication review and direct immunofluorescence in diagnostic evaluation.